AnaptysBio - Home
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Rosnilimab
ANB032
ANB033
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Core Values
Total Rewards Program Highlights
AnaptysBio Culture
Contact
Toggle
Transforming patient health by delivering innovative immunology therapeutics
May 30, 2023
AnaptysBio Announces Participation in Upcoming Investor Conferences
AnaptysBio Announces Participation in Upcoming Investor Conferences
May 11, 2023
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
May 2, 2023
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
About
Technology
Pipeline
Investors
Careers
